Boehringer Ingelheim, Lifebit Extend Clinical Data Partnership

Boehringer Ingelheim and Lifebit have extended their partnership for another three years, strengthening their commitment to enable fast, secure and scalable reuse of clinical trial data for early discovery research.

The partnership is centered on a secure, federated Trusted Research Environment (TRE), a next-generation computing environment that connects Boehringer Ingelheim’s data ecosystem and governance capabilities with Lifebit’s platform. The TRE gives scientists a single, secure and researcher-friendly interface to discover, access and analyze patient-level data while maintaining stringent data protection and compliance standards.

Lifebit’s platform is fully integrated into Boehringer Ingelheim’s internal IT landscape, providing a data management foundation for transparent, auditable and reproducible analyses. The companies said data remains under local custodianship and does not leave the secure environment, protecting sensitive clinical information while making it available for advanced research use cases.

“The Trusted Research Environment represents a core capability for enabling our scientists to work with clinical data in a secure, compliant, and highly efficient way — ultimately helping us develop novel solutions for the benefit of patients,” said Oliver Wissdorf, Head of IT RDM CI at Boehringer Ingelheim. “Lifebit has proven to be a reliable and innovative partner throughout this journey, delivering a TRE that is purpose-built to meet our specific scientific, technical, and governance requirements.”

“Boehringer Ingelheim has demonstrated a clear and forward‑looking vision for unlocking the full potential of clinical data in discovery research,” said Dr. Maria Dunford, CEO of Lifebit. “We were particularly impressed by their decisive move away from generic, horizontal tools toward purpose‑built systems co‑developed with Lifebit — and by the speed and agility with which they established a modern, secure internal data infrastructure.”

The extended partnership will focus on accelerating translational studies by combining clinical insights with additional data types within governed, auditable workflows. The companies said the approach is intended to inform drug development, support data-driven decision-making and ultimately improve patient outcomes while preserving rigorous governance and security standards.

More Boehringer Ingelheim News

Earlier this week, Owkin announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, along with multimodal patient data.